查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2086031

代謝性疾病治療市場：2026-2032年全球市場預測（依治療分類、疾病類型、治療領域、給藥途徑、患者族群、最終用戶及通路分類）

Metabolic Disorders Therapeutics Market by Treatment Classifications, Disease Type, Therapeutic Areas, Route Of Administration, Patient Demographics, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，代謝疾病治療市場規模將達到 896.8 億美元，年複合成長率為 6.31%。

主要市場統計數據
基準年 2025 584.3億美元
預計年份：2026年 615.6億美元
預測年份 2032 896.8億美元
複合年成長率 (%) 6.31%

代謝性疾病的治療正從控制慢性症狀轉向強調緩解疾病、體重管理和降低心臟代謝風險的策略。這一領域主要關注糖尿病、肥胖、血脂異常症、代謝功能障礙相關的脂肪性肝炎、罕見的先天性代謝性疾病以及相關的腎臟和心血管併發症。

這項需求得到了已證實的流行病學數據的支持。世界衛生組織（WHO）預測，到2022年，全球將有超過10億人患有肥胖症，同年全球將有約8.3億人患有糖尿病。隨著疾病負擔的日益加重，GLP-1受體促效劑、雙重和三重腸促胰島素療法、SGLT2抑制劑、降血脂藥物、RNA療法、酵素替代療法以及針對遺傳代謝疾病的商業性醫療等藥物的臨床和商業價值也日益凸顯。

治療前景的變革性變化

將肥胖症治療、糖尿病護理、肝病管理、腎臟保護和心血管疾病預防相結合，正在重塑治療模式。基於GLP-1和GIP的療法透過展現顯著的臨床減重效果和心血管代謝獲益，徹底改變了人們對治療的預期。同時，SGLT2抑制劑的應用範圍也從降低血糖擴展到心臟衰竭和慢性腎臟病等領域。

人工智慧的累積影響

人工智慧正透過標靶發現、生物標記識別、最佳化臨床試驗參與者選擇、藥物安全性監測以及產生真實世界數據（REW），加速代謝性疾病的治療。機器學習模型可以整合基因組學、影像學、電子健康記錄、連續血糖監測、實驗室檢測值和保險理賠數據，以識別高風險表現型並預測治療反應。

全球市場的關鍵區域洞察

亞太地區是代謝疾病治療的龐大市場，這主要得益於大規模的糖尿病患者族群、不斷上升的肥胖盛行率，以及中國、印度、日本、韓國和澳洲等國專科醫療服務的日益普及。國際糖尿病聯盟（IDF）一直指出，中國和印度擁有全球最大的成年糖尿病患者群體，凸顯了該地區在糖尿病治療、減肥藥、降血脂療法以及腎臟和代謝疾病治療方面的重要性。日本、澳洲和韓國擁有先進的臨床基礎設施、老化人口，並且具備廣泛推廣已證實對心血管和腎臟疾病有效的治療方法的巨大潛力。

針對特定群體的關鍵策略優先排序見解

在東南亞國協，都市化、飲食結構改變以及醫療保險覆蓋範圍的擴大導致第2型糖尿病、肥胖症和血脂異常症的診斷率和治療率上升，從而增加了醫療需求。在海灣合作理事會國家，降低糖尿病、肥胖症和心血管疾病風險是國家衛生策略的優先事項，這反映了代謝性疾病在該地區造成的沉重負擔，以及在醫療報銷體系完善、專科醫生資源豐富的地區，高品質代謝性疾病治療日益成長的重要性。

各國在代謝疾病治療的關鍵見解

美國是一個以創新主導的代謝疾病治療市場，這得益於其高肥胖率、美國疾病控制與預防中心（CDC）報告的沉重糖尿病負擔、GLP-1療法的快速普及以及對心血管、腎臟和肝臟療效的嚴格臨床證據要求。加拿大則強調平衡公共和私人醫療保險報銷，並制定基於實證醫學的處方藥清單。而墨西哥和巴西由於患者群體龐大、醫療資源可及性、可負擔性和治療連續性等問題，在糖尿病、肥胖症和降脂療法的推廣方面面臨嚴峻挑戰。

為行業領導者提供的實用建議

產業領導者應優先考慮差異化的臨床結果，包括心血管、腎臟、肝臟、血脂、功能和生活品質 (QOL) 等終點指標，而不僅限於體重減輕和血糖值降低。產品組合策略應平衡高階生物製藥與可大規模擴充性的口服療法、聯合治療、罕見代謝疾病治療以及能夠增強治療連續性和耐受性的生命週期管理。

調查方法

本執行摘要基於來自公共衛生、監管、臨床和產業領域可靠來源的二手研究，包括世界衛生組織 (WHO)、美國疾病管制與預防中心 (CDC)、國際糖尿病聯盟 (IDF)、美國食品藥物管理局 (FDA)、歐洲藥品管理局 (EMA)、經濟合作暨發展組織 (OECD)、同行評審期刊、臨床指南、臨床試驗註冊庫以及公開審查庫以及公開的資訊來源文件。本分析優先考慮檢驗的流行病學數據、已通過核准的治療藥物類別、指南相關的治療趨勢、監管里程碑以及可觀察到的市場進入趨勢。

結論：代謝疾病治療的策略展望

隨著肥胖、糖尿病、肝病、腎臟病、血脂異常症和心血管疾病的預防日益被視為相互關聯的疾病，代謝疾病治療市場正進入一個極具影響力的階段。這種轉變推動了對能夠提供持續、可衡量且多器官療效，同時改善長期疾病管理的療法的強勁需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 代謝性疾病治療市場：依治療分類

  • 酵素替代療法
  • 基因治療
  • 藥品和藥物產品
  • 小分子療法

第8章 代謝性疾病治療市場：依疾病類型分類

  • 糖尿病
    • 妊娠糖尿病
    • 1型糖尿病
    • 2型糖尿病
  • 高雪氏症
  • 血鐵沉著症
  • 高膽固醇症
  • 粒線體疾病
  • 苯酮尿症（PKU）
  • 龐貝氏症
  • 甲狀腺疾病
    • 甲狀腺功能亢進
    • 甲狀腺機能低下症
  • 尿素循環功能障礙
  • 威爾遜氏症

第9章 代謝疾病治療市場：依治療領域分類

  • 內分泌疾病
  • 遺傳性疾病
  • 營養缺乏

第10章 代謝性疾病治療藥物市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 皮下

第11章 代謝性疾病治療市場：依患者族群分類

  • 成年患者
  • 老年患者
  • 兒童患者

第12章 代謝疾病治療市場：依最終使用者分類

  • 診所
  • 居家照護環境
  • 醫院
  • 專業醫療中心

第13章 代謝疾病治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章 代謝疾病治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章 代謝性疾病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 代謝疾病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • Abbott Laboratories
  • AbbVie Inc.
  • Acadia Pharmaceuticals Inc.
  • Amgen Inc.
  • Amicus Therapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biocon Limited
  • BioMarin Pharmaceutical Inc.
  • Boehringer Ingelheim International GmbH
  • CHIESI Farmaceutici SpA
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Luye Pharma Group Ltd
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Recordati Industria Chimica e Farmaceutica SpA
  • Sanofi SA
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Industries
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
Product Code: MRR-0363DFE03688

The Metabolic Disorders Therapeutics Market is projected to grow by USD 89.68 billion at a CAGR of 6.31% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 58.43 billion
Estimated Year [2026] USD 61.56 billion
Forecast Year [2032] USD 89.68 billion
CAGR (%) 6.31%

Metabolic disorders therapeutics are moving from chronic symptom control toward disease-modifying, weight-centric, and cardiometabolic risk reduction strategies. The sector is anchored by diabetes, obesity, dyslipidemia, metabolic dysfunction-associated steatohepatitis, rare inborn errors of metabolism, and related renal and cardiovascular complications.

Demand is supported by verified epidemiology: the World Health Organization reports that more than 1 billion people were living with obesity in 2022, while diabetes affected about 830 million people worldwide in the same year. These burdens are expanding the clinical and commercial relevance of GLP-1 receptor agonists, dual and triple incretin therapies, SGLT2 inhibitors, lipid-lowering agents, RNA-based therapies, enzyme replacement approaches, and precision medicines for inherited metabolic diseases.

Transformative Shifts in the Therapeutic Landscape

The therapeutic landscape is being reshaped by the convergence of obesity medicine, diabetes care, liver disease management, kidney protection, and cardiovascular prevention. GLP-1 and GIP-based therapies have changed treatment expectations by demonstrating clinically meaningful weight loss and cardiometabolic benefits, while SGLT2 inhibitors have expanded beyond glucose lowering into heart failure and chronic kidney disease indications.

Regulatory science is also evolving. The approval of the first therapy for metabolic dysfunction-associated steatohepatitis with fibrosis in the United States signaled a new pathway for liver-metabolic drugs. At the same time, supply capacity, cold-chain reliability, payer affordability, device convenience, and long-term adherence are becoming decisive differentiators across metabolic disorders therapeutics.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is accelerating metabolic disorders therapeutics through target discovery, biomarker identification, trial enrichment, pharmacovigilance, and real-world evidence generation. Machine learning models can integrate genomics, imaging, electronic health records, continuous glucose monitoring, laboratory values, and claims data to identify high-risk phenotypes and predict treatment response.

The impact is cumulative rather than isolated. AI-enabled patient stratification can improve clinical trial efficiency, while digital adherence tools, remote monitoring, and predictive analytics can support long-term outcomes in diabetes, obesity, dyslipidemia, and fatty liver disease. However, leaders must validate algorithms across diverse populations, protect patient data, reduce bias, and satisfy evolving regulatory expectations for clinical-grade AI.

Key Regional Insights Across Global Markets

Asia-Pacific is a high-volume region for metabolic disorders therapeutics, supported by large diabetes populations in China, India, Japan, South Korea, and Australia, rising obesity prevalence, and expanding access to specialty care. The International Diabetes Federation has consistently identified China and India among the countries with the largest adult diabetes populations, reinforcing the region's importance for diabetes therapeutics, obesity drugs, lipid-lowering therapies, and renal-metabolic care. Japan, Australia, and South Korea add advanced clinical infrastructure, aging populations, and strong uptake potential for therapies with proven cardiovascular and renal outcomes.

North America remains a leading innovation and commercialization hub, supported by FDA regulatory pathways, high biologics adoption, robust clinical trial activity, and strong demand for obesity and cardiometabolic therapies. Latin America shows increasing need in Brazil and Mexico as diabetes and obesity rise, but reimbursement fragmentation and out-of-pocket exposure influence treatment continuity. Europe benefits from EMA oversight, health technology assessment discipline, and mature chronic disease programs, making comparative effectiveness and cost-effectiveness evidence central to access. The Middle East, especially Gulf markets, faces high diabetes prevalence and rapid specialty adoption, while Africa represents an underdiagnosed and access-constrained opportunity where affordable medicines, diagnostic scale-up, and primary care integration remain essential.

Key Group Insights for Strategic Prioritization

ASEAN demand is increasing as urbanization, dietary transition, and expanding health coverage raise diagnosis and treatment rates for type 2 diabetes, obesity, and dyslipidemia. GCC countries are prioritizing diabetes, obesity, and cardiovascular risk reduction through national health strategies, reflecting the region's high metabolic disease burden and the growing relevance of premium metabolic therapies where reimbursement and specialist access allow.

The European Union is shaped by centralized regulatory review, national health technology assessment decisions, prescribing guidance, and cost-effectiveness scrutiny, making outcomes evidence critical for metabolic disorders therapeutics. BRICS countries combine large patient pools with varied pricing controls, access disparities, and local manufacturing priorities, particularly in diabetes medicines and cardiometabolic drugs. G7 markets lead in advanced incretin, lipid, renal-metabolic, and rare metabolic disease therapy adoption due to mature reimbursement systems and strong clinical infrastructure, while NATO countries increasingly frame medicine supply resilience, domestic capacity, and logistics security as part of broader health security planning.

Key Country Insights in Metabolic Disorders Therapeutics

The United States is an innovation-led market for metabolic disorders therapeutics, supported by high obesity prevalence, a substantial CDC-reported diabetes burden, rapid adoption of GLP-1 therapies, and strong clinical evidence requirements for cardiovascular, renal, and hepatic outcomes. Canada emphasizes a public-private reimbursement balance and evidence-based formulary decisions, while Mexico and Brazil offer large patient populations with persistent access, affordability, and care-continuity constraints that shape uptake of diabetes, obesity, and lipid-lowering therapies.

The United Kingdom, Germany, France, Italy, and Spain are guided by health technology assessment, prescribing protocols, budget impact reviews, and chronic disease pathways, making real-world outcomes and cost-offset evidence essential. Russia remains access-sensitive amid geopolitical and supply constraints. China and India combine massive diabetes and obesity-related disease burdens with price competition, expanding local manufacturing, and growing demand for scalable oral and injectable therapies. Japan, Australia, and South Korea offer advanced clinical infrastructure, aging populations, high standards for safety, and strong demand for long-term cardiometabolic treatments that reduce complications across diabetes, obesity, dyslipidemia, kidney disease, and cardiovascular risk.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated clinical outcomes beyond weight loss or glucose reduction, including cardiovascular, renal, hepatic, lipid, functional, and quality-of-life endpoints. Portfolio strategy should balance premium biologics with scalable oral therapies, combination regimens, rare metabolic disease treatments, and lifecycle management that improves persistence and tolerability.

Organizations should build manufacturing redundancy, device-fill capacity, active pharmaceutical ingredient security, and cold-chain resilience to avoid supply bottlenecks in high-demand therapeutic classes. Market access teams should generate real-world evidence that supports cost offsets in diabetes complications, cardiovascular events, liver fibrosis progression, kidney disease outcomes, and hospitalization risk. Partnerships with diagnostics, digital health, primary care networks, and specialist clinics can strengthen patient identification, adherence, monitoring, and equitable access.

Research Methodology

This executive summary is based on secondary research from recognized public health, regulatory, clinical, and industry sources, including WHO, CDC, IDF, FDA, EMA, OECD, peer-reviewed journals, clinical guidelines, clinical trial registries, and public regulatory documents. The analysis prioritizes verified epidemiology, approved therapeutic classes, guideline-relevant treatment trends, regulatory milestones, and observable market access dynamics.

Insights were triangulated across disease burden, product innovation, reimbursement, regional access, healthcare infrastructure, and therapeutic adoption patterns. No unverified market-size, market-share, or forecast claims are used. Strategic conclusions reflect evidence-based interpretation of published data, regulatory actions, disease management priorities, and current clinical practice trends in metabolic disorders therapeutics.

Conclusion: Strategic Outlook for Metabolic Therapeutics

The metabolic disorders therapeutics market is entering a high-impact phase in which obesity, diabetes, liver disease, kidney disease, dyslipidemia, and cardiovascular prevention are increasingly treated as connected conditions. This shift supports strong demand for therapies that deliver durable, measurable, and multi-organ benefits while improving long-term disease management.

Future leadership will depend on evidence quality, differentiated outcomes, scalable manufacturing, equitable access, payer-ready real-world data, and responsible use of AI. Organizations that combine scientific innovation with region-specific commercialization models, resilient supply chains, and strong adherence support will be best positioned to capture long-term strategic value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Metabolic Disorders Therapeutics Market, by Treatment Classifications

  • 7.1. Enzyme Replacement Therapies
  • 7.2. Gene Therapies
  • 7.3. Medications & Drugs
  • 7.4. Small Molecule Therapy

8. Metabolic Disorders Therapeutics Market, by Disease Type

  • 8.1. Diabetes Mellitus
    • 8.1.1. Gestational Diabetes
    • 8.1.2. Type 1 Diabetes
    • 8.1.3. Type 2 Diabetes
  • 8.2. Gaucher's Disease
  • 8.3. Hemochromatosis
  • 8.4. Hypercholesterolemia
  • 8.5. Mitochondrial Disorders
  • 8.6. Phenylketonuria (PKU)
  • 8.7. Pompe Disease
  • 8.8. Thyroid Disorders
    • 8.8.1. Hyperthyroidism
    • 8.8.2. Hypothyroidism
  • 8.9. Urea Cycle Disorders
  • 8.10. Wilson's Disease

9. Metabolic Disorders Therapeutics Market, by Therapeutic Areas

  • 9.1. Endocrine Disorders
  • 9.2. Genetic Disorders
  • 9.3. Nutritional Disorders

10. Metabolic Disorders Therapeutics Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Subcutaneous

11. Metabolic Disorders Therapeutics Market, by Patient Demographics

  • 11.1. Adult Patients
  • 11.2. Geriatric Patients
  • 11.3. Pediatric Patients

12. Metabolic Disorders Therapeutics Market, by End User

  • 12.1. Clinics
  • 12.2. Homecare Settings
  • 12.3. Hospitals
  • 12.4. Specialty Centers

13. Metabolic Disorders Therapeutics Market, by Distribution Channel

  • 13.1. Hospital Pharmacies
  • 13.2. Online Pharmacies
  • 13.3. Retail Pharmacies

14. Metabolic Disorders Therapeutics Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Metabolic Disorders Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Metabolic Disorders Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. Abbott Laboratories
  • 18.2. AbbVie Inc.
  • 18.3. Acadia Pharmaceuticals Inc.
  • 18.4. Amgen Inc.
  • 18.5. Amicus Therapeutics, Inc.
  • 18.6. Astellas Pharma Inc.
  • 18.7. AstraZeneca plc
  • 18.8. Bayer AG
  • 18.9. Biocon Limited
  • 18.10. BioMarin Pharmaceutical Inc.
  • 18.11. Boehringer Ingelheim International GmbH
  • 18.12. CHIESI Farmaceutici S.p.A.
  • 18.13. Dr. Reddy's Laboratories Ltd.
  • 18.14. Eli Lilly and Company
  • 18.15. F. Hoffmann-La Roche Ltd
  • 18.16. GlaxoSmithKline PLC
  • 18.17. Glenmark Pharmaceuticals Limited
  • 18.18. Johnson & Johnson Services, Inc.
  • 18.19. Lupin Limited
  • 18.20. Luye Pharma Group Ltd
  • 18.21. Merck & Co., Inc.
  • 18.22. Novartis AG
  • 18.23. Novo Nordisk A/S
  • 18.24. Otsuka Holdings Co., Ltd.
  • 18.25. Pfizer Inc.
  • 18.26. Recordati Industria Chimica e Farmaceutica S.p.A
  • 18.27. Sanofi S.A.
  • 18.28. Sumitomo Pharma Co., Ltd.
  • 18.29. Sun Pharmaceutical Industries
  • 18.30. Takeda Pharmaceutical Company Limited
  • 18.31. Teva Pharmaceutical Industries Ltd.
  • 18.32. Torrent Pharmaceuticals Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENZYME REPLACEMENT THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENZYME REPLACEMENT THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENZYME REPLACEMENT THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENE THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENE THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MEDICATIONS & DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MEDICATIONS & DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MEDICATIONS & DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SMALL MOLECULE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SMALL MOLECULE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SMALL MOLECULE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DIABETES MELLITUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIABETES MELLITUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DIABETES MELLITUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GESTATIONAL DIABETES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GESTATIONAL DIABETES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GESTATIONAL DIABETES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GAUCHER'S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GAUCHER'S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GAUCHER'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEMOCHROMATOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HEMOCHROMATOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEMOCHROMATOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HYPERCHOLESTEROLEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HYPERCHOLESTEROLEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HYPERCHOLESTEROLEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MITOCHONDRIAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MITOCHONDRIAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MITOCHONDRIAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PHENYLKETONURIA (PKU) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PHENYLKETONURIA (PKU) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PHENYLKETONURIA (PKU) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL POMPE DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL POMPE DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL POMPE DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL THYROID DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL THYROID DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL THYROID DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HYPERTHYROIDISM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HYPERTHYROIDISM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HYPERTHYROIDISM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HYPOTHYROIDISM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HYPOTHYROIDISM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HYPOTHYROIDISM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL UREA CYCLE DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL UREA CYCLE DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL UREA CYCLE DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL WILSON'S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL WILSON'S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL WILSON'S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ENDOCRINE DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENDOCRINE DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ENDOCRINE DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENETIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENETIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENETIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NUTRITIONAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NUTRITIONAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NUTRITIONAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ADULT PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ADULT PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ADULT PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GERIATRIC PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GERIATRIC PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GERIATRIC PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL SPECIALTY CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL SPECIALTY CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL SPECIALTY CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. GCC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. GCC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2032 (USD MILLION)
  • TABLE 188. GCC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. GCC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2032 (USD MILLION)
  • TABLE 190. GCC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 191. GCC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 192. GCC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. GCC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 194. GCC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. GCC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. G7 METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 217. G7 METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2032 (USD MILLION)
  • TABLE 218. G7 METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. G7 METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2032 (USD MILLION)
  • TABLE 220. G7 METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 221. G7 METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 222. G7 METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. G7 METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 224. G7 METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. G7 METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. NATO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. NATO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2032 (USD MILLION)
  • TABLE 228. NATO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. NATO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2032 (USD MILLION)
  • TABLE 230. NATO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 231. NATO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 232. NATO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. NATO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 234. NATO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. NATO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2032 (USD MILLION)
  • TABLE 249. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2032 (USD MILLION)
  • TABLE 251. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 252. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 253. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 254. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 255. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 257. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2032 (USD MILLION)
  • TABLE 259. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2032 (USD MILLION)
  • TABLE 261. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 262. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 263. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 264. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 265. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 268. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2032 (USD MILLION)
  • TABLE 269. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2032 (USD MILLION)
  • TABLE 271. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 272. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 273. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 275. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 287. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 288. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2032 (USD MILLION)
  • TABLE 289. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2032 (USD MILLION)
  • TABLE 291. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 292. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 293. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 294. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 295. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 297. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 298. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2032 (USD MILLION)
  • TABLE 299. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2032 (USD MILLION)
  • TABLE 301. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 302. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 303. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 304. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 305. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 306. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 307. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 308. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2032 (USD MILLION)
  • TABLE 309. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2032 (USD MILLION)
  • TABLE 311. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 312. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 313. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 314. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 315. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 316. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 317. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 318. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2032 (USD MILLION)
  • TABLE 319. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2032 (USD MILLION)
  • TABLE 321. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 322. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 323. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 324. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 325. ITALY META